{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:33Z","timestamp":1792783413508,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"ABPI","id":[{"id":"https:\/\/ror.org\/02hgpw430","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40273-026-01636-x","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:18:25Z","timestamp":1783941505000},"page":"1281-1297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimisation or Restriction? Unpacking the Logic Behind NICE Decisions"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-9376","authenticated-orcid":false,"given":"Nadine","family":"Henderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6232-7168","authenticated-orcid":false,"given":"Brittany","family":"Darrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9016-402X","authenticated-orcid":false,"given":"Phill","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-4743","authenticated-orcid":false,"given":"Martina","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"1636_CR1","unstructured":"NICE. Compliance with NICE-approved medicines or treatments, NICE website: The National Institute for Health and Care Excellence. [Online]. https:\/\/www.nice.org.uk\/what-nice-does\/our-guidance\/about-technology-appraisal-guidance\/compliance-with-nice-approved-medicines-or-treatments. Accessed 23 Apr 2026."},{"key":"1636_CR2","unstructured":"NICE. 6 Committee recommendations | NICE technology appraisal and highly specialised technologies guidance: the manual | guidance | NICE\u2019 [Online]. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/committee-recommendations-2#recommending-a-technology. Accessed 23 Apr 2026."},{"key":"1636_CR3","unstructured":"NICE. Technology appraisal data: appraisal recommendations, Technology appraisal data: appraisal recommendations. [Online]. https:\/\/www.nice.org.uk\/what-nice-does\/[[...slug]]. Accessed 02 Dec 2025."},{"key":"1636_CR4","unstructured":"NICE. Technology appraisal data: appraisal recommendations, NICE. [Online]. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/data\/appraisal-recommendations. Accessed 13 Mar 2025."},{"issue":"11","key":"1636_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2165\/11536970-000000000-00000","volume":"28","author":"P O\u2019Neill","year":"2010","unstructured":"O\u2019Neill P, Devlin NJ. An analysis of NICE\u2019s \u201crestricted\u201d (or \u201coptimized\u201d) decisions. Pharmacoeconomics. 2010;28(11):987\u201393. https:\/\/doi.org\/10.2165\/11536970-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"1636_CR6","unstructured":"Bulut M, O\u2019Neill P, Cole A. NICE \u201coptimised\u201d decisions: what is the recommended level of patient access?. Office of Health Economics; 2020. [Online]. https:\/\/www.ohe.org\/wp-content\/uploads\/2020\/07\/OHE-Analysis-of-NICE-Optimised-decisions-July-2020.pdf. Accessed 07 Mar 2025."},{"key":"1636_CR7","unstructured":"Henderson N. How restrictive are NICE \u201coptimised\u201d decisions?. Office of Health Economics. [Online]. https:\/\/www.ohe.org\/insight\/how-restrictive-nice-optimised-decisions. Accessed 13 Mar 2025."},{"issue":"12","key":"1636_CR8","doi-asserted-by":"publisher","first-page":"S357","DOI":"10.1016\/j.jval.2023.09.1878","volume":"26","author":"I Maslyankov","year":"2023","unstructured":"Maslyankov I, Bajela E, King M, Tang S. HTA195 optimized recommendations in NICE technology appraisals: permissive or restrictive? Value Health. 2023;26(12):S357. https:\/\/doi.org\/10.1016\/j.jval.2023.09.1878.","journal-title":"Value Health"},{"key":"1636_CR9","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"key":"1636_CR10","unstructured":"NICE. 5 Developing the guidance | NICE technology appraisal and highly specialised technologies guidance: the manual | guidance | NICE\u2019. NICE, Jan. 31, 2022. [Online]. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/developing-the-guidance-2. Accessed 17 Feb 2026."},{"key":"1636_CR11","unstructured":"NICE. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta989. Accessed 12 May 2026."},{"key":"1636_CR12","unstructured":"NICE. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1015. Accessed 12 May 2026."},{"key":"1636_CR13","unstructured":"NICE. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1023. Accessed 12 May 2026."},{"key":"1636_CR14","unstructured":"NICE. Voxelotor for treating haemolytic anaemia caused by sickle cell disease. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta981. Accessed 12 May 2026."},{"key":"1636_CR15","unstructured":"NICE. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta943. Accessed 12 May 2026."},{"key":"1636_CR16","unstructured":"NICE. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta985. Accessed 12 May 2026."},{"key":"1636_CR17","unstructured":"NICE. Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma. [Online]. http:\/\/www.nice.org.uk\/guidance\/ta858. Accessed 24 Apr 2026."},{"key":"1636_CR18","unstructured":"NICE. Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta878. Accessed 24 Apr 2026."},{"key":"1636_CR19","unstructured":"NICE. Daratumumab with bortezomib and dexamethassone for previously treated multiple myeloma. 2022."},{"key":"1636_CR20","unstructured":"NICE. Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta947. Accessed 24 Apr 2026."},{"key":"1636_CR21","unstructured":"NICE. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta913. Accessed 25 Apr 2026."},{"key":"1636_CR22","unstructured":"NICE. Dabrafenib for treating unresectable or metastatic BRAF V600 mutation\u2011positive melanoma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta321. Accessed 24 Apr 2026."},{"key":"1636_CR23","unstructured":"NICE. Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1010. Accessed 24 Apr 2026."},{"key":"1636_CR24","unstructured":"NICE. Empagliflozin for treating chronic kidney disease. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta942. Accessed 24 Apr 2026."},{"key":"1636_CR25","unstructured":"NICE. Finerenone for treating chronic kidney disease in type 2 diabetes. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta877. Accessed 24 Apr 2026."},{"key":"1636_CR26","unstructured":"NICE. Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta874. Accessed 24 Apr 2026."},{"key":"1636_CR27","unstructured":"NICE. Risankizumab for previously treated moderately to severely active Crohn\u2019s disease. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta888. Accessed 24 Apr 2026."},{"key":"1636_CR28","unstructured":"NICE. Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta974. Accessed 24 Apr 2026."},{"key":"1636_CR29","unstructured":"NICE. Targeted-release budesonide for treating primary IgA nephropathy. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1128. Accessed 24 Apr 2026."},{"key":"1636_CR30","unstructured":"NICE. Ublituximab for treating relapsing multiple sclerosis: guidance. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1025\/resources. Accessed 18 Feb 2026."},{"key":"1636_CR31","unstructured":"NICE. Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta914. Accessed 24 Apr 2026."},{"key":"1636_CR32","unstructured":"NICE. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta967. Accessed 24 Apr 2026."},{"key":"1636_CR33","unstructured":"NICE. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta939. Accessed 24 Apr 2026."},{"key":"1636_CR34","unstructured":"NICE. Abaloparatide for treating osteoporosis after menopause. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta991. Accessed 24 Apr 2026."},{"key":"1636_CR35","unstructured":"NICE. Daridorexant for treating long-term insomnia. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta922. Accessed 24 Apr 2026"},{"key":"1636_CR36","unstructured":"NICE. Deucravacitinib for treating moderate to severe plaque psoriasis | Guidance | NICE. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta907. Accessed 24 Apr 2026."},{"key":"1636_CR37","unstructured":"NICE. Latanoprost\u2013netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1009. Accessed 24 Apr 2026."},{"key":"1636_CR38","unstructured":"NICE. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta986. Accessed 24 Apr 2026."},{"key":"1636_CR39","unstructured":"NICE. TA919: Rimegepant for treating migraine. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta919. Accessed 21 Jan 2026."},{"key":"1636_CR40","unstructured":"NICE. Secukinumab for treating moderate to severe hidradenitis suppurativa. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta935. Accessed 24 Apr 2026."},{"key":"1636_CR41","unstructured":"NICE. Upadacitinib for previously treated moderately to severely active Crohn\u2019s disease. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta905. Accessed 24 Apr 2026."},{"key":"1636_CR42","unstructured":"NICE. Upadacitinib for treating active non-radiographic axial spondyloarthritis. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta861. Accessed 24 Apr 2026."},{"key":"1636_CR43","unstructured":"NICE. Atogepant for preventing migraine. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta973. Accessed 24 Apr 2026."},{"key":"1636_CR44","unstructured":"NICE. Bimekizumab for treating active psoriatic arthritis. [Online]. Available: https:\/\/www.nice.org.uk\/guidance\/ta916. Accessed 24 Apr 2026."},{"key":"1636_CR45","unstructured":"NICE. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1021. Accessed 24 Apr 2026."},{"key":"1636_CR46","unstructured":"NICE. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta954. Accessed 24 Apr 2026."},{"key":"1636_CR47","unstructured":"NICE. Eptinezumab for preventing migraine. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta871. Accessed 24 Apr 2026."},{"key":"1636_CR48","unstructured":"NICE. Foslevodopa\u2013foscarbidopa for treating advanced Parkinson\u2019s with motor symptoms. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta934. Accessed 24 Apr 2026."},{"key":"1636_CR49","unstructured":"NICE. Mirikizumab for treating moderately to severely active ulcerative colitis. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta925. Accesse 24 Apr 2026."},{"key":"1636_CR50","unstructured":"NICE. Nivolumab\u2013relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta950. Accessed 24 Apr 2026."},{"key":"1636_CR51","unstructured":"NICE, \u2018TA906: Rimegepant for preventing migraine\u2019. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta906\/chapter\/2-Information-about-rimegepant. Accessed 21 Jan 2026."},{"key":"1636_CR52","unstructured":"NICE. Tezepelumab for treating severe asthma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta880. Accessed 24 Apr 2026."},{"key":"1636_CR53","unstructured":"NICE. Tirzepatide for managing overweight and obesity. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1026. Accessed 24 Apr 2026."},{"key":"1636_CR54","unstructured":"NICE. Tofacitinib for treating active ankylosing spondylitis. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta920. Accessed 24 Apr 2026."},{"key":"1636_CR55","unstructured":"NICE. Semaglutide for managing overweight and obesity. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta875. Accessed 24 Apr 2026."},{"key":"1636_CR56","unstructured":"NICE. Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta918. Accessed 24 Apr 2026."},{"key":"1636_CR57","unstructured":"NICE. Bulevirtide for treating chronic hepatitis D. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta896. Accessed 24 Apr 2026."},{"key":"1636_CR58","unstructured":"NICE. Cannabidiol for treating seizures caused by tuberous sclerosis complex. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta873. Accessed 24 Apr 2026."},{"key":"1636_CR59","unstructured":"NICE. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1018. Accessed 24 Apr 2026."},{"key":"1636_CR60","unstructured":"NICE. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta870. Accessed 24 Apr 2026."},{"key":"1636_CR61","unstructured":"NICE. Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta908. Accessed 24 Apr 2026."},{"key":"1636_CR62","unstructured":"NICE. Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta911. Accessed 24 Apr 2026."},{"key":"1636_CR63","unstructured":"NICE. Vibegron for treating symptoms of overactive bladder syndrome. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta999. Accessed 24 Apr 2026."},{"key":"1636_CR64","unstructured":"NICE. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta964. Accessed 24 Apr 2026."},{"key":"1636_CR65","unstructured":"NICE. Zanubrutinib for treating chronic lymphocytic leukaemia. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta931. Accessed 24 Apr 2026."},{"key":"1636_CR66","unstructured":"NICE. Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta865\/chapter\/1-Recommendations. Accessed 24 Apr 2026."},{"key":"1636_CR67","unstructured":"NICE. Linzagolix for treating moderate to severe symptoms of uterine fibroids. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta996. Accessed 24 Apr 2026."},{"issue":"12","key":"1636_CR68","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1080\/14737175.2024.2434079","volume":"24","author":"L Edvinsson","year":"2024","unstructured":"Edvinsson L. Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence. Expert Rev Neurother. 2024;24(12):1141\u201355. https:\/\/doi.org\/10.1080\/14737175.2024.2434079.","journal-title":"Expert Rev Neurother"},{"key":"1636_CR69","unstructured":"Sanger K. New research reveals devastating impact of living with migraine, yet condition still not taken seriously, The Migraine Trust. [Online]. https:\/\/migrainetrust.org\/research-devastating-impact-of-migraine\/. Accessed 23 Jan 2026."},{"issue":"2","key":"1636_CR70","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s12325-022-02369-x","volume":"40","author":"LC Powell","year":"2023","unstructured":"Powell LC, et al. Health state utility mapping of rimegepant for the preventive treatment of migraine: double-blind treatment phase and open label extension (BHV3000-305). Adv Ther. 2023;40(2):585\u2013600. https:\/\/doi.org\/10.1007\/s12325-022-02369-x.","journal-title":"Adv Ther"},{"key":"1636_CR71","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12875-023-02242-y","volume":"25","author":"D Kernick","year":"2024","unstructured":"Kernick D, et al. Preventive treatment patterns in the adult migraine population: an observational UK study over 7 years. BMC Prim Care. 2024;25:34. https:\/\/doi.org\/10.1186\/s12875-023-02242-y.","journal-title":"BMC Prim Care"},{"key":"1636_CR72","unstructured":"NICE. More than 20,000 people benefitting from innovative migraine pills recommended by NICE, NICE website: The National Institute for Health and Care Excellence. [Online]. https:\/\/www.nice.org.uk\/news\/articles\/more-than-20-000-people-benefitting-from-innovative-migraine-pills-recommended-by-nice. Accessed 02 Mar 2026."},{"issue":"1","key":"1636_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain. 2022;23(1):67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"issue":"8","key":"1636_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037297","volume":"103","author":"M Haki","year":"2024","unstructured":"Haki M, AL-Biati HA, Al-Tameemi ZS, Ali IS, Al-hussaniy HA. Review of multiple sclerosis: epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024;103(8):e37297. https:\/\/doi.org\/10.1097\/MD.0000000000037297.","journal-title":"Medicine (Baltimore)"},{"key":"1636_CR75","unstructured":"NICE. Ublituximab for treating relapsing multiple sclerosis: committee Papers. 2024. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta1025\/documents\/committee-papers. Accessed 02 April 2026."},{"issue":"8","key":"1636_CR76","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","volume":"97","author":"BAC Cree","year":"2021","unstructured":"Cree BAC, et al. Secondary progressive multiple sclerosis. Neurology. 2021;97(8):378\u201388. https:\/\/doi.org\/10.1212\/WNL.0000000000012323.","journal-title":"Neurology"},{"key":"1636_CR77","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.7.857","author":"A McKenna","year":"2023","unstructured":"McKenna A, et al. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value. J Manag Care Spec Pharm. 2023. https:\/\/doi.org\/10.18553\/jmcp.2023.29.7.857.","journal-title":"J Manag Care Spec Pharm"},{"key":"1636_CR78","unstructured":"NICE. Dimethyl fumarate for treating relapsing\u2011remitting multiple sclerosis. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta320\/chapter\/1-Recommendations. Accessed 20 Feb 2026."},{"issue":"8","key":"1636_CR79","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387(8):704\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2201904.","journal-title":"N Engl J Med"},{"issue":"1","key":"1636_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.474","volume":"5","author":"SCL Caseby","year":"2022","unstructured":"Caseby SCL, Woodhouse FA, Montgomery SM, Kroes MA, Duddy ME. Transition to secondary progressive multiple sclerosis: the consequences for patients and healthcare systems, a healthcare professional survey. Health Sci Rep. 2022;5(1):e474. https:\/\/doi.org\/10.1002\/hsr2.474.","journal-title":"Health Sci Rep"},{"issue":"1","key":"1636_CR81","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200064","volume":"10","author":"T Ziemssen","year":"2022","unstructured":"Ziemssen T, et al. Secondary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200064. https:\/\/doi.org\/10.1212\/NXI.0000000000200064.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"1636_CR82","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1606038.","journal-title":"N Engl J Med"},{"key":"1636_CR83","unstructured":"NICE. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. [Online]. https:\/\/www.nice.org.uk\/guidance\/ta897\/chapter\/3-Committee-discussion. Accessed 18 Feb 2026."},{"issue":"1","key":"1636_CR84","doi-asserted-by":"publisher","first-page":"29","DOI":"10.18553\/jmcp.2018.24.1.29","volume":"24","author":"JJ Carlson","year":"2018","unstructured":"Carlson JJ, et al. Cost-effectiveness of drugs to treat relapsed\/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2018;24(1):29\u201338. https:\/\/doi.org\/10.18553\/jmcp.2018.24.1.29.","journal-title":"J Manag Care Spec Pharm"},{"key":"1636_CR85","unstructured":"NICE. Assessing the resource impact of NICE guidance, NICE website: The National Institute for Health and Care Excellence. [Online]. https:\/\/www.nice.org.uk\/implementing-nice-guidance\/[[...slug]]. Accessed 23 Jan 2026."},{"key":"1636_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1011082","volume":"9","author":"MP Hofer","year":"2022","unstructured":"Hofer MP, Criscuolo P, Shah N, ter Wal ALJ, Barlow J. Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: initial insights. Front Med. 2022;9:1011082. https:\/\/doi.org\/10.3389\/fmed.2022.1011082.","journal-title":"Front Med"},{"key":"1636_CR87","unstructured":"NICE. Types of recommendation NICE can make, NICE website: The National Institute for Health and Care Excellence. [Online]. https:\/\/www.nice.org.uk\/what-nice-does\/[[...slug]]. Accessed 20 Jan 2026."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01636-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:43:09Z","timestamp":1790343789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01636-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1636"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01636-x","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employed by the Office of Health Economics, a registered charity and Independent Research Organisation, which receives funding from a variety of private and public sector sources.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data and materials analysed are available on the NICE website (\n                      \n                      ) for the respective technology appraisals.","order":2,"name":"Ethics","label":"Availability of data and materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. Acquisition, analysis and interpretation of the data was performed by Brittany Darrow, Nadine Henderson and Phill O\u2019Neill. The first draft of the manuscript was written by Nadine Henderson and Brittany Darrow; all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript for publication.","order":3,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}